As markets continue to assess the impact of coronavirus (COVID-19), the Templeton Global Macro team shares an update on the economic and market implications, which they say could be more detrimental—and last longer—than many observers previously thought.
New information on the coronavirus (COVID-19) continues to arrive daily; however, the peak magnitude of the epidemic and the full extent of the economic implications are still unknowable at this point.
Markets appear to be pricing-in a V-shaped recovery as the base case for the Chinese economy and global growth, though some concerns over the longevity of the economic impact have appeared to affect risk assets in recent days. There are signs that the duration and scope of the economic impacts will be greater for COVID-19 than they were for SARS (Severe Acute Respiratory Syndrome) in 2003.
Notably, China’s economy is massively larger today than it was in 2003—more than eight times the size.1 It is also substantially more integrated into the global economy and more extensively linked into global supply chains. Today, China represents 16% of global gross domestic product (GDP), up from 4% in 2003.2
Supply chains have already started to see the effects of factory shutdowns. Notably, Apple issued a revenue warning this week for its March quarter, due in part to specific factories being unable to open. Around 500 million3 people have been in a virtual lockdown across the country. Hubei province, the epicenter of the virus outbreak and an area under significant quarantine, is a key location for electronics and technology manufacturing.
Consumption and travel sectors within China and regionally continue to be significantly impaired. Additionally, commodity imports into China have been disrupted as factory shutdowns have halted the manufacturing sector’s demand for external resources, such as petroleum and metals.
Of additional concern is the fact that COVID-19 is far more prolific than SARS was, increasing the likelihood that it will persist for much longer. It is highly contagious and has long asymptomatic incubation periods of up to 14 days.
Carriers that don’t know they’re sick can spread the disease to others over the course of weeks. Additionally, a significant percentage of cases only show mild symptoms,4 such as a low-grade sore throat, which carriers may not recognize as COVID-19 and may not accordingly take actions to avoid spreading the virus.
By contrast, SARS could only be spread to others after symptoms appeared, making it less likely to be unwittingly transmitted. The higher severity of SARS symptoms also drew carriers away from the public.
COVID-19 does have a significantly lower fatality rate (2%) than SARS (10%).5 Additionally, only around one in five infected people become severely ill,6 with around four in five confirmed cases exhibiting only mild symptoms.
However, COVID-19 is 20 to 40 times more fatal than the average seasonal flu7 and has approximately double the reproduction rate.8 At this stage, COVID-19 is projected to infect tens of thousands of more people than SARS did,9 with expectations for more than 100,000 confirmed cases.
Consequently, COVID-19 is a far more pervasive and stealthy disease than SARS, which has necessitated a stronger response from the Chinese government, leading to widespread containment efforts and longer quarantine periods. These measures may be justified to stop the spread, but they are also exceedingly disruptive to economic activity, bringing communities and businesses to a standstill.
Some virologists10 have modeled scenarios that show the disease potentially persisting for more than a year. Under such conditions, governments would need to respond with ever-more aggressive containment measures, potentially paralyzing economies beyond China.
At this stage, we are continuing to monitor developments and watching for any signs that COVID-19 has meaningfully permeated communities beyond China.
From a financial market standpoint, we think the tail risks of a more prolonged and higher magnitude disruption from COVID-19 remain underappreciated by markets. We continue to see elevated global risks, and continue to position our strategies to be uncorrelated to overvalued asset classes. The rapid spread of COVID-19 is a stark reminder than unexpected events can occur at any time, and that portfolio diversification remains critical when markets are priced for perfection.
Important Legal Information
This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice.
Any companies and case studies shown herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton Investments. The opinions are intended solely to provide insight into how securities are analyzed. The information provided is not a recommendation or individual investment advice for any particular security, strategy, or investment product and is not an indication of the trading intent of any Franklin Templeton managed portfolio. This is not a complete analysis of every material fact regarding any industry, security or investment and should not be viewed as an investment recommendation. This is intended to provide insight into the portfolio selection and research process. Factual statements are taken from sources considered reliable but have not been independently verified for completeness or accuracy. These opinions may not be relied upon as investment advice or as an offer for any particular security. Past performance is not an indicator or a guarantee of future results.
The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as of publication date and may change without notice. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market.
Data from third party sources may have been used in the preparation of this material and Franklin Templeton (“FT”) has not independently verified, validated or audited such data. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.
Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own professional adviser or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.
Issued in the U.S. by Franklin Templeton Distributors, Inc., One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com—Franklin Templeton Distributors, Inc. is the principal distributor of Franklin Templeton’s U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.
This information is intended for US residents only.
1. According to the National Bureau of Statistics of China, GDP in USD terms was $14.36 trillion in 2019, and $1.66 trillion in 2003.
2. The World Bank.
3. Reuters reported around 500 million people affected by quarantines and travel restrictions, as of February 14. https://graphics.reuters.com/CHINA-HEALTH-LOCKDOWN/0100B5EF3LJ/index.html
4. China CDC Weekly published results of 44,672 confirmed cases as of February 11, 2020. Case severity was observed as 81% of patients having mild symptoms, 14% developing severe symptoms as pneumonia, 5% becoming critical. The observed fatality rate was 2.3%.
5. World Health Organization (WHO) reports the fatality rate of SARS in 2002/2003 to be have been 9.6% of total confirmed cases. WHO estimates the current fatality rate of COVID-19 to be around 2%, as of February 18.
6. China CDC Weekly published results of 44,672 confirmed cases as of February 11, 2020. Case severity was observed as 81% of patients having mild symptoms, 14% developing severe symptoms as pneumonia, 5% becoming critical. The observed fatality rate was 2.3%.
7. Center for Disease Control and Prevention (CDC) estimates around a 0.05% fatality rate for seasonal flu in the Unites States in the 2019/2020 period. The estimated 1% to 2% fatality rate of COVID-19 is around twenty to forty times higher. https://www.livescience.com/new-coronavirus-compare-with-flu.html
8. World Health Organization (WHO) estimates the reproduction ratio (R0) of the common flu to be 1.3. It had estimated the COVID-19 R0 to be between 1.5 and 2.5, as of January 30. A January 29 study by the New England Journal of Medicine estimated COVID-19 to be 2.2.
9. Known cases were more than 72,000 as of February 18, 2020 according to WHO, and expected to continue to rise. SARS cases were 8,096)
10. CDC Director Robert Redfield publicly commented in an interview with CNN on February 13 that, “this virus (COVID-19) is probably with us beyond this season, beyond this year. I think eventually the virus will gain a foothold and we will get community-based transmission.” https://www.cnn.com/2020/02/13/health/coronavirus-cdc-robert-redfield-gupta-intv/index.html
© Franklin Templeton Investments
© Franklin Templeton Investments
Read more commentaries by Franklin Templeton Investments
